PREVAIL Act

House Bill

H.R. 3160

119th Congress

PREVAIL Act

In Committee

Introduced:Oct 8, 2025

Primary Sponsor

Chellie Pingree

Representative

Democratic

ME-1

Cosponsors

1

Quick Stats

Policy Area

Health

Summary

The Pharmaceutical Research Transparency Act would require the disclosure of costs associated with clinical trials and pharmaceutical research and development. It would create a public registry of cost data for certain clinical trials and mandate that drug manufacturers report their research and development expenditures to the Securities and Exchange Commission.

Latest Action

Referred to the Subcommittee on Health.

SponsorChellie Pingree (D-ME)

Introduced10/8/2025

StatusReferred to the House Committee on the Judiciary.

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

PREVAIL Act

The Pharmaceutical Research Transparency Act would require the disclosure of costs associated with clinical trials and pharmaceutical research and development. It would create a public registry of cost data for certain clinical trials and mandate that drug man

Community Breakdown

Pass

0%

Fail

0%

0 predictions

The Pharmaceutical Research Transparency Act would require the disclosure of costs associated with clinical trials and pharmaceutical research and development. It would create a public registry of cost data for certain clinical trials and mandate that drug manufacturers report their research and development expenditures to the Securities and Exchange Commission.

Bill Number: 3160
Sponsor: Chellie Pingree (D-ME)
Introduced: 10/8/2025
Status: Referred to the House Committee on the Judiciary.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: PREVAIL Act
Bill Number: 3160
Sponsor: Chellie Pingree (D-ME)
Status: Referred to the House Committee on the Judiciary.
Introduced: 10/8/2025
Summary: The Pharmaceutical Research Transparency Act would require the disclosure of costs associated with clinical trials and pharmaceutical research and development. It would create a public registry of cost data for certain clinical trials and mandate that drug manufacturers report their research and dev

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

The Pharmaceutical Research Transparency Act would require the disclosure of costs associated with clinical trials and pharmaceutical research and development. It would create a public registry of cost data for certain clinical trials and mandate that drug manufacturers report their research and development expenditures to the Securities and Exchange Commission.

Last updated: 12/29/2025

Official Summary

Congressional Research Service summary

Pharmaceutical Research Transparency Act of 2023 This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development. Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion. The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.

Key Points

Main provisions of the bill

Requires the National Institutes of Health to create a public registry of cost data, including total and per-patient costs, for certain clinical trials testing drugs, biological products, and devices.
Mandates that drug manufacturers include their research and development expenditures in their annual disclosures to the Securities and Exchange Commission.
Aims to increase transparency around the costs of pharmaceutical research and development.

How This Impacts Americans

Potential effects on citizens and communities

If this bill becomes law, it would affect pharmaceutical companies, patients, and the general public. Increased transparency around the costs of drug development could inform policy decisions and help patients understand the pricing of medications. The public registry could also provide valuable information for researchers and healthcare providers.

Policy Areas

Primary Policy Area

Health

Related Subjects

Administrative law and regulatory procedures

Department of Health and Human Services

Government information and archives

Manufacturing

Medical research

Prescription drugs

Research and development

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

3160, 119th Congress (2025). "PREVAIL Act". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-3160

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.